Talked to Your Peers Lately? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Talked to Your Peers Lately?
Forums, blogs, and more can spark innovation.


Pharmaceutical Technology


Angie Drakulich
We recently added a callout to the end of our peer-reviewed articles, but we're not sure you've seen it. The red icon asks for your input on the published paper: What would you have done differently if it had been your experiment, your process, or your equipment? We, and the authors of the research papers herein, would like your feedback.

We welcome you to email your thoughts to us at
regarding any peer-reviewed papers, or any articles for that matter, that appear in the magazine or on our website and we'll post your comments in a special online section at the end of the appropriate article. Our goal is to encourage more discussion among industry peers to promote the exchange of ideas and ultimately, innovation.

In fact, we just launched a call for nominations for the 2008 Innovations in Pharma Science Awards, which will honor achievements in the pharmaceutical sciences. Check out http://pharmtech.com/Innovations to nominate your company's work in one of five areas: drug delivery, formulation, dosage forms, pharmaceutical analysis, and API synthesis. The winners will be announced in the December issue.

PharmTech also has a daily blog, http://blog.pharmtech.com/, where you can exchange ideas with the editors and experts by commenting on current posts, or adding your own post. What better way is there to increase your industry knowledge and advance your on-the-job skills than to talk to those people doing the same thing you're doing? So join us online and let's get talking.

Angie Drakulich is the managing editor of Pharmaceutical Technology,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here